CD86 and neoplasm: Upon establishing the binding specificity of AYA22T-R2-13 to CTLA-4 on cytotoxic T lymphocytes (CTLs), our investigation aimed to uncover its potential in enhancing CTL-mediated tumor cell lysis by disrupting CTLA-4 interactions with the CD80 or CD86 axis.